RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up

Key Takeaways RXRX reported a Q4 loss of 21 cents per share, beating estimates and narrowing from last year.Recursion revenues rose to $35.5M on a $30M Roche milestone payment and contributions from Sanofi.Recursion Pharmaceuticals ended 2025 with $753.9M in cash, funding operations into early 2028.Recursion Pharmaceuticals (RXRX) reported a loss of 21 cents per share in the fourth quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 28 cents. The company had incurred a loss of 53 cents ...